Trazodone and Bosulif (Bosutinib) Drug Interaction
There is no direct pharmacokinetic interaction between trazodone and bosutinib, but caution is warranted due to potential additive QT prolongation risk and the fact that both drugs can affect cardiac function.
Key Interaction Considerations
CYP3A4 Metabolism Pathway
Bosutinib is primarily metabolized by CYP3A4 1, 2, while trazodone is also a CYP3A4 substrate. However, neither drug is a strong CYP3A4 inhibitor or inducer at therapeutic doses, so clinically significant pharmacokinetic interactions through this pathway are unlikely.
Critical Safety Concerns
The FDA label for bosutinib explicitly warns about cardiac toxicity, including cardiac failure, left ventricular dysfunction, and cardiac ischemic events 3. Patients should be monitored for:
- Shortness of breath
- Weight gain
- Fluid retention
- Signs of cardiac ischemia
Trazodone carries a known risk of QT prolongation, particularly at higher doses. When combined with bosutinib (which can cause cardiovascular toxicity), there is theoretical concern for additive cardiac effects.
Practical Management Recommendations
You can use these medications together with appropriate monitoring:
- Baseline ECG before initiating combination therapy
- Monitor for cardiac symptoms including palpitations, syncope, or dyspnea
- Avoid other QT-prolonging agents when possible
- Consider dose adjustment if cardiac symptoms emerge
- Regular cardiac monitoring in patients with pre-existing cardiac disease
Drug Interaction Warnings from FDA Label
The bosutinib FDA label states that "BOSULIF and certain other medicines, including over the counter medications or herbal supplements can interact with each other and may alter the effects of BOSULIF" 3. However, trazodone is not specifically listed as a contraindicated or cautionary medication 3.
Important Caveats
- Strong CYP3A4 inhibitors and inducers should be avoided with bosutinib 3, but trazodone does not fall into these categories
- Proton pump inhibitors should be avoided; use short-acting antacids or H2 blockers instead 3
- Bosutinib can inhibit drug transporters (OCT2, MATE1, BCRP) 4, but trazodone is not a significant substrate of these transporters
Monitor closely for cardiac symptoms and consider cardiology consultation if the patient has pre-existing cardiac disease or is on multiple medications affecting cardiac conduction.